1 of 1
Roche's Drug Setback
- Roche Holding AG reported that giredestrant failed to meet the primary endpoint in a late-stage study, and its shares fell about 7.5%.
- The trial showed no significant difference in disease progression between giredestrant and standard therapy.
- Roche remains optimistic, citing prior studies indicating potential benefits.
- Roche will continue development with a trial expected to report results in 2027.
- Analysts say the drug could still have commercial potential despite recent disappointments.
